ReviewBiomicrofluidics2016
Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine.
Review in Biomicrofluidics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Light Scattering Contrast Inversion of Single Metal Nanoparticles Inside a Nanofluidic Channel.The journal of physical chemistry. C, Nanomaterials and interfaces · 2026Article
- Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use.Frontiers in reproductive health · 2024Article
- Liquid Biopsy and Circulating Biomarkers for the Diagnosis of Precancerous and Cancerous Oral Lesions.Non-coding RNA · 2022Review
- Toward the Development of Rapid, Specific, and Sensitive Microfluidic Sensors: A Comprehensive Device Blueprint.JACS Au · 2021Review
- Article
- Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation.Cancers · 2021Review
- [Advances of Exosomes Extraction and Its Mechanism in Early Diagnosis of Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
- Liquid biopsy technologies based on membrane microfluidics: High-yield purification and selective quantification of biomarkers in nanocarriers.Electrophoresis · 2020Review
- Chemically tailoring nanopores for single-molecule sensing and glycomics.Analytical and bioanalytical chemistry · 2020Article
- Resistive amplitude fingerprints during translocation of linear molecules through charged solid-state nanopores.The Journal of chemical physics · 2020Article
- Hydrophobically Coated Superparamagnetic Iron Oxides Nanoparticles Incorporated into Polymer-Based Nanocapsules Dispersed in Water.Materials (Basel, Switzerland) · 2020Article
- Sensor-Integrated Microfluidic Approaches for Liquid Biopsies Applications in Early Detection of Cancer.Sensors (Basel, Switzerland) · 2020Review
- Review
- Recent advances in microfluidic methods in cancer liquid biopsy.Biomicrofluidics · 2019Review
- MicroRNA amplification and detection technologies: opportunities and challenges for point of care diagnostics.Laboratory investigation; a journal of technical methods and pathology · 2019Review
- Extracellular vesicle microRNA quantification from plasma using an integrated microfluidic device.Communications biology · 2019Article
- Solid-state nanopore hydrodynamics and transport.Biomicrofluidics · 2019Article
- Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis.Critical reviews in clinical laboratory sciences · 2018Review
- Electrokinetic ion transport in nanofluidics and membranes with applications in bioanalysis and beyond.Biomicrofluidics · 2018Review
- Rapid detection of exosomal microRNA biomarkers by electrokinetic concentration for liquid biopsy on chip.Biomicrofluidics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Nucleic acid biomarkers have enormous potential in non-invasive diagnostics and disease management. In medical research and in the near future in the clinics, there is a great demand for accurate miRNA, mRNA, and ctDNA identification and profiling. They may lead to screening of early stage cancer that is not detectable by tissue biopsy or imaging. Moreover, because their cost is low and they are non-invasive, they can become a regular screening test during annual checkups or allow a dynamic treatment program that adjusts its drug and dosage frequently. We briefly review a few existing viral and endogenous RNA assays that have been approved by the Federal Drug Administration. These tests are based on the main nucleic acid detection technologies, namely, quantitative reverse transcription polymerase chain reaction (PCR), microarrays, and next-generation sequencing. Several of the challenges that these three technologies still face regarding the quantitative measurement of a panel of nucleic acids are outlined. Finally, we review a cluster of microfluidic technologies from our group with potential for point-of-care nucleic acid quantification without nucleic acid amplification, designed to overcome specific limitations of current technologies. We suggest that integration of these technologies in a modular design can offer a low-cost, robust, and yet sensitive/selective platform for a variety of precision medicine applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.